首页 > 最新文献

PATHOLOGICA最新文献

英文 中文
Author's reply to the Letter to the Editor from Mungunpuntipantip and Wiwanitkit. 作者对Mungunputiantip和Wiwanitkit给编辑的信的回复。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-08-01 DOI: 10.32074/1591-951X-917
Ilaria Girolami
{"title":"Author's reply to the Letter to the Editor from Mungunpuntipantip and Wiwanitkit.","authors":"Ilaria Girolami","doi":"10.32074/1591-951X-917","DOIUrl":"10.32074/1591-951X-917","url":null,"abstract":"","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 4","pages":"247"},"PeriodicalIF":3.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10283959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Livedoid skin reaction and mRNA Covid-19 vaccine: correspondence. 活皮肤反应与mRNA新冠肺炎疫苗:对应关系。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-08-01 DOI: 10.32074/1591-951X-806
Rujittika Mungunpuntipantip, Viroj Wiwanitkit
{"title":"Livedoid skin reaction and mRNA Covid-19 vaccine: correspondence.","authors":"Rujittika Mungunpuntipantip, Viroj Wiwanitkit","doi":"10.32074/1591-951X-806","DOIUrl":"10.32074/1591-951X-806","url":null,"abstract":"","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 4","pages":"246"},"PeriodicalIF":3.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10283962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antepartum unscarred uterine rupture caused by placenta percreta: a case report and literature review. 先天性胎盘致产前无瘢痕子宫破裂1例并文献复习。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-08-01 DOI: 10.32074/1591-951X-882
Eleonora Nardi, Viola Seravalli, Isabella Abati, Francesca Castiglione, Mariarosaria Di Tommaso

The main risk for uterine rupture is the presence of a uterine scar due to prior cesarean delivery or other uterine surgery. However, rupture in an unscarred uterus is extremely rare, and risk factors include multiple gestations, trauma, congenital anomalies, use of uterotonics and placenta accreta spectrum.

Placenta accreta spectrum, also known as morbidly adherent placenta, is becoming increasingly common and is associated with significant maternal and neonatal morbidity and mortality.

We report a case of unscarred uterine rupture due to placenta percreta in a multiparous woman that required emergency peripartum hysterectomy.

子宫破裂的主要风险是由于先前剖宫产或其他子宫手术造成的子宫疤痕。然而,无瘢痕子宫破裂极为罕见,其危险因素包括多胎妊娠、外伤、先天性异常、使用子宫强直术和胎盘增生谱。胎盘增生谱,也被称为病态附着性胎盘,正变得越来越普遍,并与显著的孕产妇和新生儿发病率和死亡率相关。我们报告一例无瘢痕子宫破裂,由于percreta胎盘在多胎妇女需要紧急围产期子宫切除术。
{"title":"Antepartum unscarred uterine rupture caused by placenta percreta: a case report and literature review.","authors":"Eleonora Nardi, Viola Seravalli, Isabella Abati, Francesca Castiglione, Mariarosaria Di Tommaso","doi":"10.32074/1591-951X-882","DOIUrl":"10.32074/1591-951X-882","url":null,"abstract":"<p><p>The main risk for uterine rupture is the presence of a uterine scar due to prior cesarean delivery or other uterine surgery. However, rupture in an unscarred uterus is extremely rare, and risk factors include multiple gestations, trauma, congenital anomalies, use of uterotonics and placenta accreta spectrum.</p><p><p>Placenta accreta spectrum, also known as morbidly adherent placenta, is becoming increasingly common and is associated with significant maternal and neonatal morbidity and mortality.</p><p><p>We report a case of unscarred uterine rupture due to placenta percreta in a multiparous woman that required emergency peripartum hysterectomy.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 4","pages":"232-236"},"PeriodicalIF":3.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10287240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective. 结直肠腺癌RAS检测的理想报告:病理学家的观点。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-06-14 DOI: 10.32074/1591-951X-895
Umberto Malapelle, Valentina Angerilli, Francesco Pepe, Gabriella Fontanini, Sara Lonardi, Mario Scartozzi, Lorenzo Memeo, Gianfranco Pruneri, Antonio Marchetti, Giuseppe Perrone, Matteo Fassan

RAS gene mutational status represents an imperative predictive biomarker to be tested in the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the most studied biomarkers in the era of precision medicine, several pre-analytical and analytical factors may still impasse an adequate reporting of RAS status in clinical practice, with significant therapeutic consequences. Thus, pathologists should be aware on the main topics related to this molecular evaluation: (i) adopt diagnostic limit of detections adequate to avoid the interference of sub-clonal cancer cell populations; (ii) choose the most adequate diagnostic strategy according to the available sample and its qualification for molecular testing; (iii) provide all the information regarding the mutation detected, since many RAS mutation-specific targeted therapeutic approaches are in development and will enter into routine clinical practice. In this review, we give a comprehensive description of the current scenario about RAS gene mutational testing in the clinic focusing on the pathologist's role in patient selection for targeted therapies.

在转移性结直肠癌的临床治疗中,RAS基因突变状态是一种重要的预测性生物标志物。即使它是精准医学时代研究最多的生物标志物之一,一些分析前和分析因素可能仍然会阻碍临床实践中RAS状态的充分报告,并产生重大的治疗后果。因此,病理学家应该意识到与这种分子评估相关的主要主题:(i)采用足够的诊断检测限制,以避免亚克隆癌细胞群的干扰;(ii)根据可获得的样本及其分子检测资格选择最适当的诊断策略;(iii)提供有关检测到的突变的所有信息,因为许多针对RAS突变的靶向治疗方法正在开发中,并将进入常规临床实践。在这篇综述中,我们对目前临床中RAS基因突变检测的情况进行了全面的描述,重点是病理学家在患者选择靶向治疗中的作用。
{"title":"The ideal reporting of <i>RAS</i> testing in colorectal adenocarcinoma: a pathologists' perspective.","authors":"Umberto Malapelle,&nbsp;Valentina Angerilli,&nbsp;Francesco Pepe,&nbsp;Gabriella Fontanini,&nbsp;Sara Lonardi,&nbsp;Mario Scartozzi,&nbsp;Lorenzo Memeo,&nbsp;Gianfranco Pruneri,&nbsp;Antonio Marchetti,&nbsp;Giuseppe Perrone,&nbsp;Matteo Fassan","doi":"10.32074/1591-951X-895","DOIUrl":"https://doi.org/10.32074/1591-951X-895","url":null,"abstract":"<p><p><i>RAS</i> gene mutational status represents an imperative predictive biomarker to be tested in the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the most studied biomarkers in the era of precision medicine, several pre-analytical and analytical factors may still impasse an adequate reporting of <i>RAS</i> status in clinical practice, with significant therapeutic consequences. Thus, pathologists should be aware on the main topics related to this molecular evaluation: (i) adopt diagnostic limit of detections adequate to avoid the interference of sub-clonal cancer cell populations; (ii) choose the most adequate diagnostic strategy according to the available sample and its qualification for molecular testing; (iii) provide all the information regarding the mutation detected, since many <i>RAS</i> mutation-specific targeted therapeutic approaches are in development and will enter into routine clinical practice. In this review, we give a comprehensive description of the current scenario about <i>RAS</i> gene mutational testing in the clinic focusing on the pathologist's role in patient selection for targeted therapies.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/60/pathol-2023-03-137.PMC10462993.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10107819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The slow-paced digital evolution of pathology: lights and shadows from a multifaceted board. 慢节奏的数字化病理学进化:多面板上的光和影。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-06-01 DOI: 10.32074/1591-951X-868
Alessandro Caputo, Vincenzo L'Imperio, Francesco Merolla, Ilaria Girolami, Eleonora Leoni, Vincenzo Della Mea, Fabio Pagni, Filippo Fraggetta

Objective: The digital revolution in pathology represents an invaluable resource fto optimise costs, reduce the risk of error and improve patient care, even though it is still adopted in a minority of laboratories. Barriers include concerns about initial costs, lack of confidence in using whole slide images for primary diagnosis, and lack of guidance on transition. To address these challenges and develop a programme to facilitate the introduction of digital pathology (DP) in Italian pathology departments, a panel discussion was set up to identify the key points to be considered.

Methods: On 21 July 2022, an initial conference call was held on Zoom to identify the main issues to be discussed during the face-to-face meeting. The final summit was divided into four different sessions: (I) the definition of DP, (II) practical applications of DP, (III) the use of AI in DP, (IV) DP and education.

Results: Essential requirements for the implementation of DP are a fully tracked and automated workflow, selection of the appropriate scanner based on the specific needs of each department, and a strong commitment combined with coordinated teamwork (pathologists, technicians, biologists, IT service and industries). This could reduce human error, leading to the application of AI tools for diagnosis, prognosis and prediction. Open challenges are the lack of specific regulations for virtual slide storage and the optimal storage solution for large volumes of slides.

Conclusion: Teamwork is key to DP transition, including close collaboration with industry. This will ease the transition and help bridge the gap that currently exists between many labs and full digitisation. The ultimate goal is to improve patient care.

目的:病理学的数字革命代表了优化成本,降低错误风险和改善患者护理的宝贵资源,即使它仍然在少数实验室中采用。障碍包括对初始费用的担忧,对使用整个幻灯片图像进行初步诊断缺乏信心,以及缺乏过渡指导。为了应对这些挑战并制定一项计划,以促进在意大利病理学部门引入数字病理学(DP),建立了一个小组讨论,以确定需要考虑的关键点。方法:2022年7月21日,在Zoom上举行了首次电话会议,以确定面对面会议期间要讨论的主要问题。最后的峰会分为四个不同的会议:(I)数据处理的定义,(II)数据处理的实际应用,(III)人工智能在数据处理中的应用,(IV)数据处理与教育。结果:实施DP的基本要求是完全跟踪和自动化的工作流程,根据每个部门的具体需求选择合适的扫描仪,以及与协调的团队合作(病理学家,技术人员,生物学家,IT服务和行业)相结合的坚定承诺。这可以减少人为错误,从而将人工智能工具应用于诊断、预后和预测。开放的挑战是缺乏对虚拟幻灯片存储的具体规定,以及对大量幻灯片的最佳存储解决方案。结论:团队合作是DP转型的关键,包括与行业的密切合作。这将简化过渡,并有助于弥合目前许多实验室与完全数字化之间存在的差距。最终目标是改善对病人的护理。
{"title":"The slow-paced digital evolution of pathology: lights and shadows from a multifaceted board.","authors":"Alessandro Caputo,&nbsp;Vincenzo L'Imperio,&nbsp;Francesco Merolla,&nbsp;Ilaria Girolami,&nbsp;Eleonora Leoni,&nbsp;Vincenzo Della Mea,&nbsp;Fabio Pagni,&nbsp;Filippo Fraggetta","doi":"10.32074/1591-951X-868","DOIUrl":"https://doi.org/10.32074/1591-951X-868","url":null,"abstract":"<p><strong>Objective: </strong>The digital revolution in pathology represents an invaluable resource fto optimise costs, reduce the risk of error and improve patient care, even though it is still adopted in a minority of laboratories. Barriers include concerns about initial costs, lack of confidence in using whole slide images for primary diagnosis, and lack of guidance on transition. To address these challenges and develop a programme to facilitate the introduction of digital pathology (DP) in Italian pathology departments, a panel discussion was set up to identify the key points to be considered.</p><p><strong>Methods: </strong>On 21 July 2022, an initial conference call was held on Zoom to identify the main issues to be discussed during the face-to-face meeting. The final summit was divided into four different sessions: (I) the definition of DP, (II) practical applications of DP, (III) the use of AI in DP, (IV) DP and education.</p><p><strong>Results: </strong>Essential requirements for the implementation of DP are a fully tracked and automated workflow, selection of the appropriate scanner based on the specific needs of each department, and a strong commitment combined with coordinated teamwork (pathologists, technicians, biologists, IT service and industries). This could reduce human error, leading to the application of AI tools for diagnosis, prognosis and prediction. Open challenges are the lack of specific regulations for virtual slide storage and the optimal storage solution for large volumes of slides.</p><p><strong>Conclusion: </strong>Teamwork is key to DP transition, including close collaboration with industry. This will ease the transition and help bridge the gap that currently exists between many labs and full digitisation. The ultimate goal is to improve patient care.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 3","pages":"127-136"},"PeriodicalIF":3.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/f1/pathol-2023-03-127.PMC10462988.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10489971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical implications of Cytokeratin 19 expression in patients with oral squamous cell carcinoma. 口腔鳞状细胞癌细胞角蛋白19表达的临床意义。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-06-01 DOI: 10.32074/1591-951X-842
Nur Rahadiani, Sarwanti Sarwanti, Diah Rini Handjari, Marini Stephanie, Ening Krisnuhoni

Objective: This study was done to quantify the prevalence of high cytokeratin (CK) 19 expression in Indonesian oral squamous cell carcinoma (OSCC) patients and explore the prognostic role of CK19 in OSCC.

Methods: Clinical data and samples from 61 patients diagnosed with OSCC at a tertiary national referral hospital in Jakarta, Indonesia were analyzed in this retrospective cohort study. Immunohistochemical staining of CK19 was performed on all patients and its expression was scored using the H system. All patients were followed up for a minimum of 36 months after diagnosis. Comparative and survival analyses were performed.

Results: Twenty six point two percent of Indonesian OSCC patients had high CK19 expression. There were no differences in clinicopathological characteristics between patients with low and high CK19 expression. The 3-year overall survival (OS) of our cohort was 11.5%. Patients with high CK19 expression had lower 3-year OS compared to patients with low CK19 expression, even if the difference in OS was not statistically significant. Keratinization was an independent prognostic factor for survival in multivariate regression analysis.

Conclusions: Data obtained here indicate a possible prognostic role of CK19 in OSCC. This prognostic role should be confirmed in larger series.

目的:本研究旨在量化印尼口腔鳞状细胞癌(OSCC)患者中细胞角蛋白(CK) 19高表达的患病率,并探讨CK19在OSCC中的预后作用。方法:回顾性队列研究分析了印度尼西亚雅加达一家三级国家转诊医院61例OSCC患者的临床资料和样本。对所有患者进行CK19免疫组化染色,并用H系统对其表达进行评分。所有患者在确诊后至少随访36个月。进行了比较分析和生存分析。结果:26.2%的印尼OSCC患者CK19高表达。CK19低表达与高表达患者的临床病理特征无差异。我们队列的3年总生存率(OS)为11.5%。与CK19低表达患者相比,CK19高表达患者的3年OS较低,即使OS差异无统计学意义。在多变量回归分析中,角化是一个独立的预后因素。结论:本文获得的数据表明CK19在OSCC中可能具有预后作用。这种预后作用应在更大的系列中得到证实。
{"title":"Clinical implications of Cytokeratin 19 expression in patients with oral squamous cell carcinoma.","authors":"Nur Rahadiani,&nbsp;Sarwanti Sarwanti,&nbsp;Diah Rini Handjari,&nbsp;Marini Stephanie,&nbsp;Ening Krisnuhoni","doi":"10.32074/1591-951X-842","DOIUrl":"https://doi.org/10.32074/1591-951X-842","url":null,"abstract":"<p><strong>Objective: </strong>This study was done to quantify the prevalence of high cytokeratin (CK) 19 expression in Indonesian oral squamous cell carcinoma (OSCC) patients and explore the prognostic role of CK19 in OSCC.</p><p><strong>Methods: </strong>Clinical data and samples from 61 patients diagnosed with OSCC at a tertiary national referral hospital in Jakarta, Indonesia were analyzed in this retrospective cohort study. Immunohistochemical staining of CK19 was performed on all patients and its expression was scored using the H system. All patients were followed up for a minimum of 36 months after diagnosis. Comparative and survival analyses were performed.</p><p><strong>Results: </strong>Twenty six point two percent of Indonesian OSCC patients had high CK19 expression. There were no differences in clinicopathological characteristics between patients with low and high CK19 expression. The 3-year overall survival (OS) of our cohort was 11.5%. Patients with high CK19 expression had lower 3-year OS compared to patients with low CK19 expression, even if the difference in OS was not statistically significant. Keratinization was an independent prognostic factor for survival in multivariate regression analysis.</p><p><strong>Conclusions: </strong>Data obtained here indicate a possible prognostic role of CK19 in OSCC. This prognostic role should be confirmed in larger series.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 3","pages":"155-163"},"PeriodicalIF":3.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/7a/pathol-2023-03-155.PMC10462989.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10489974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intratumoural metastasis of primary lung adenocarcinoma to non-invasive follicular thyroid neoplasm with papillary-like nuclear features. 原发性肺腺癌向具有乳头状核特征的非侵袭性滤泡甲状腺肿瘤的瘤内转移。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-06-01 DOI: 10.32074/1591-951X-780
Subhash Yadav, Suman Kumar Ankathi, Asawari Patil, Rajiv Kaushal

Metastasis to the thyroid gland is very uncommon with an incidence of 2-3% of all thyroid malignancies. A higher incidence is noted in autopsy studies indicating incidental detection. However, tumour-to-tumour metastasis is extremely uncommon with a handful of cases published in the literature to date. Also, non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P) is a rare neoplasm; diagnosis requires meticulous sampling of the entire capsule and fulfilment of other diagnostic criteria. We report a case of primary adenocarcinoma of lung in a 57-year-old female who additionally had a left thyroid nodule which appeared suspicious on ultrasonography. Histology of lung tumour was conventional papillary adenocarcinoma while aspiration cytology from the thyroid raised suspicion of metastatic adenocarcinoma. On hemithyroidectomy, the thyroid nodule showed metastatic adenocarcinoma in the centre of the nodule, while the peripheral portion showed non-invasive follicular thyroid neoplasm with papillary-like nuclear features; the diagnosis of which was confirmed with complete sampling of the thyroid capsule. The immunoprofile also supported the above dual histology. This is an extremely uncommon occurrence and metastasis within a NIFT-P has not been reported to the best of our knowledge.

甲状腺转移是非常罕见的,发病率为2-3%的所有甲状腺恶性肿瘤。在尸检研究中注意到较高的发病率,表明偶然发现。然而,肿瘤到肿瘤的转移极为罕见,迄今为止文献中仅发表了少数病例。此外,具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤(NIFT-P)是一种罕见的肿瘤;诊断需要对整个胶囊进行细致的采样,并满足其他诊断标准。我们报告一个57岁女性的原发性肺腺癌病例,她同时有左侧甲状腺结节,超声检查显示可疑。肺肿瘤组织学为常规乳头状腺癌,甲状腺细胞学检查怀疑为转移性腺癌。半甲状腺切除术中,甲状腺结节中心为转移性腺癌,周围部分为无浸润性滤泡性甲状腺肿瘤,核呈乳头状;甲状腺包膜的完整取样证实了其诊断。免疫图谱也支持上述双重组织学。这是一种非常罕见的情况,据我们所知,在NIFT-P内转移尚未报道。
{"title":"Intratumoural metastasis of primary lung adenocarcinoma to non-invasive follicular thyroid neoplasm with papillary-like nuclear features.","authors":"Subhash Yadav,&nbsp;Suman Kumar Ankathi,&nbsp;Asawari Patil,&nbsp;Rajiv Kaushal","doi":"10.32074/1591-951X-780","DOIUrl":"https://doi.org/10.32074/1591-951X-780","url":null,"abstract":"<p><p>Metastasis to the thyroid gland is very uncommon with an incidence of 2-3% of all thyroid malignancies. A higher incidence is noted in autopsy studies indicating incidental detection. However, tumour-to-tumour metastasis is extremely uncommon with a handful of cases published in the literature to date. Also, non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P) is a rare neoplasm; diagnosis requires meticulous sampling of the entire capsule and fulfilment of other diagnostic criteria. We report a case of primary adenocarcinoma of lung in a 57-year-old female who additionally had a left thyroid nodule which appeared suspicious on ultrasonography. Histology of lung tumour was conventional papillary adenocarcinoma while aspiration cytology from the thyroid raised suspicion of metastatic adenocarcinoma. On hemithyroidectomy, the thyroid nodule showed metastatic adenocarcinoma in the centre of the nodule, while the peripheral portion showed non-invasive follicular thyroid neoplasm with papillary-like nuclear features; the diagnosis of which was confirmed with complete sampling of the thyroid capsule. The immunoprofile also supported the above dual histology. This is an extremely uncommon occurrence and metastasis within a NIFT-P has not been reported to the best of our knowledge.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 3","pages":"186-191"},"PeriodicalIF":3.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/4a/pathol-2023-03-186.PMC10462986.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10116091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shortage of pathologists in Italy: survey of students and residents. 意大利病理学家短缺:对学生和居民的调查。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-06-01 DOI: 10.32074/1591-951X-852
Giuseppe D'Abbronzo, Stefano Lucà, Emma Carraturo, Renato Franco, Andrea Ronchi

Objective: In Italy, shortage of pathologists is a problem that affects the quality of the National Health System (NHS). The cause of the shortage of pathologists in Italy must be sought in the lack of interests in the pathologist career by Medical Course Students (MCS) and in drop out of Post-Graduate Medical Schools (PGMS). We investigated reasons of both through two surveys.

Methods: We developed and proposed on Facebook two surveys, one to MCSs attending last years of study and one to Pathology School Residents (PSRs). Survey for MCSs consisted of 10 questions centered on their perception about pathologist activity; survey for PSRs consisted of 8 questions and investigated the most and least appreciated aspects of Italian PGMS.

Results: We obtained 500 responses from the MCSs and 51 responses from the PSRs. Our results show that lack of interest of MCS may be due to their incomplete knowledge of the pathologist's activities. On the other hand, PSR answers show that some teaching aspects should be improved.

Conclusions: Our surveys showed that lack of interest of MCS in the pathology career depends on poor knowledge about the real clinical significance of pathology and PSRs believe that Italian PGMS do not meet their interest. One solution could be a renewal of teaching both in the pathology courses for MCS and in PGMS.

目的:在意大利,病理学家短缺是一个影响国家卫生系统(NHS)质量的问题。意大利病理学家短缺的原因必须从医学课程学生(MCS)对病理学家职业缺乏兴趣和研究生医学院(PGMS)的辍学中寻找。我们通过两次调查来调查两者的原因。方法:我们在Facebook上开发并提出了两项调查,一项针对最近几年参加研究的mcs,另一项针对病理学校住院医师(PSRs)。对MCSs的调查包括10个问题,主要围绕他们对病理学家活动的看法;PSRs调查包括8个问题,调查了意大利PGMS最受欢迎和最不受欢迎的方面。结果:我们从mcs获得了500份回复,从psr获得了51份回复。我们的研究结果表明,MCS缺乏兴趣可能是由于他们对病理学家的活动不完全了解。另一方面,PSR的回答表明,一些教学方面需要改进。结论:我们的调查显示,MCS对病理学职业缺乏兴趣取决于对病理学真正临床意义的认识不足,psr认为意大利PGMS不符合他们的兴趣。一个解决方案可能是更新MCS和PGMS病理学课程的教学。
{"title":"Shortage of pathologists in Italy: survey of students and residents.","authors":"Giuseppe D'Abbronzo,&nbsp;Stefano Lucà,&nbsp;Emma Carraturo,&nbsp;Renato Franco,&nbsp;Andrea Ronchi","doi":"10.32074/1591-951X-852","DOIUrl":"https://doi.org/10.32074/1591-951X-852","url":null,"abstract":"<p><strong>Objective: </strong>In Italy, shortage of pathologists is a problem that affects the quality of the National Health System (NHS). The cause of the shortage of pathologists in Italy must be sought in the lack of interests in the pathologist career by Medical Course Students (MCS) and in drop out of Post-Graduate Medical Schools (PGMS). We investigated reasons of both through two surveys.</p><p><strong>Methods: </strong>We developed and proposed on Facebook two surveys, one to MCSs attending last years of study and one to Pathology School Residents (PSRs). Survey for MCSs consisted of 10 questions centered on their perception about pathologist activity; survey for PSRs consisted of 8 questions and investigated the most and least appreciated aspects of Italian PGMS.</p><p><strong>Results: </strong>We obtained 500 responses from the MCSs and 51 responses from the PSRs. Our results show that lack of interest of MCS may be due to their incomplete knowledge of the pathologist's activities. On the other hand, PSR answers show that some teaching aspects should be improved.</p><p><strong>Conclusions: </strong>Our surveys showed that lack of interest of MCS in the pathology career depends on poor knowledge about the real clinical significance of pathology and PSRs believe that Italian PGMS do not meet their interest. One solution could be a renewal of teaching both in the pathology courses for MCS and in PGMS.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 3","pages":"172-180"},"PeriodicalIF":3.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/2f/pathol-2023-03-172.PMC10462991.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10116139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas. SMARCA4作为低分化肺癌鉴别诊断的支持。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-06-01 DOI: 10.32074/1591-951X-847
Martina Panozzi, Greta Alì, Agnese Proietti, Franca Melfi, Carmelina C Zirafa, Marco Lucchi, Gabriella Fontanini

Among non-small cell lung cancers (NSCLCs), sarcomatoid carcinomas account for 3%. They are rare tumours with a poor prognosis, classified into three subgroups, namely pleomorphic carcinoma, pulmonary blastoma and carcinosarcoma. In the 5th edition of WHO Classification of Thoracic Tumours more space is given to SMARC4-deficient lung cancers. Although studies on SMARCA4-deficient lung tumours are limited, a small percentage of SMARCA4 loss is present within NSCLCs. This finding is clinically relevant, as the loss of the SMARCA4 gene is associated with a worse prognosis. In our study, we analysed the presence of the main catalytic subunit of the SMARCA4 gene, the BRG1 protein, in 60 sarcomatoid lung tumours. The results of our study show that 5.3% of sarcomatoid carcinomas have BRG1-loss in tumour cells, proving that a non-negligible amount of lung sarcomatoid carcinomas are SMARCA4-deficient. These data open the debate on the necessity of including the detection of SMARCA4 within a standardised immunohistochemical panel.

在非小细胞肺癌(nsclc)中,肉瘤样癌占3%。它们是一种预后不良的罕见肿瘤,可分为3个亚组,即多形性癌、肺母细胞瘤和癌肉瘤。在第5版WHO胸椎肿瘤分类中,对smarc4缺陷型肺癌给予了更多的空间。尽管对缺乏SMARCA4的肺肿瘤的研究有限,但在非小细胞肺癌中存在一小部分SMARCA4缺失。这一发现具有临床相关性,因为SMARCA4基因的缺失与较差的预后相关。在我们的研究中,我们分析了60例肉瘤样肺肿瘤中SMARCA4基因的主要催化亚基BRG1蛋白的存在。我们的研究结果显示,5.3%的肉瘤样癌肿瘤细胞中存在brg1缺失,这证明了不可忽视的数量的肺肉瘤样癌是缺乏smarca4的。这些数据开启了关于在标准化免疫组织化学小组中包括SMARCA4检测的必要性的辩论。
{"title":"SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas.","authors":"Martina Panozzi,&nbsp;Greta Alì,&nbsp;Agnese Proietti,&nbsp;Franca Melfi,&nbsp;Carmelina C Zirafa,&nbsp;Marco Lucchi,&nbsp;Gabriella Fontanini","doi":"10.32074/1591-951X-847","DOIUrl":"https://doi.org/10.32074/1591-951X-847","url":null,"abstract":"<p><p>Among non-small cell lung cancers (NSCLCs), sarcomatoid carcinomas account for 3%. They are rare tumours with a poor prognosis, classified into three subgroups, namely pleomorphic carcinoma, pulmonary blastoma and carcinosarcoma. In the 5th edition of WHO Classification of Thoracic Tumours more space is given to SMARC4-deficient lung cancers. Although studies on SMARCA4-deficient lung tumours are limited, a small percentage of SMARCA4 loss is present within NSCLCs. This finding is clinically relevant, as the loss of the SMARCA4 gene is associated with a worse prognosis. In our study, we analysed the presence of the main catalytic subunit of the SMARCA4 gene, the BRG1 protein, in 60 sarcomatoid lung tumours. The results of our study show that 5.3% of sarcomatoid carcinomas have BRG1-loss in tumour cells, proving that a non-negligible amount of lung sarcomatoid carcinomas are SMARCA4-deficient. These data open the debate on the necessity of including the detection of SMARCA4 within a standardised immunohistochemical panel.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 3","pages":"164-171"},"PeriodicalIF":3.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/97/pathol-2023-03-164.PMC10462990.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10116134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
POLE exonuclease domain mutations in endometrial carcinoma: a case report. 子宫内膜癌中POLE外切酶结构域突变1例报告。
IF 3.5 Q1 PATHOLOGY Pub Date : 2023-05-01 DOI: 10.32074/1591-951X-872
Maria Paola Pasciuto, Lara Felicioni, Claudia Zampacorta, Benedetta Ferro, Pietro Di Marino, Francesca Chiara Primavera, Alessandro Lucidi, Rebecca Rossetti, Mattia Barbareschi, Antonio Marchetti, Fiamma Buttitta, Emanuela D'Angelo

Endometrial carcinoma (EC) harboring POLE exonuclease domain mutations occurs in 5-15% of ECs and frequently affects young women with low body mass index (BMI). It presents at early stage as high grade endometrioid histotype with intense tumor infiltrating lymphocytes and has good clinical outcomes and favorable prognosis. In this article we report the case of a 32-year-old woman with endometriod EC (EEC) exhibiting a "ultramutated" molecular profile and an excellent prognosis despite tumor size and grading. Herein, to highlight the importance of defining POLE status in ECs for both clinical and therapeutic implications for patients.

子宫内膜癌(EC)携带极外切酶结构域突变发生在5-15%的子宫内膜癌中,经常影响低体重指数(BMI)的年轻女性。早期表现为高级别子宫内膜样组织型,伴强烈肿瘤浸润淋巴细胞,临床预后良好。在这篇文章中,我们报告了一例32岁的女性子宫内膜异位症(EEC),尽管肿瘤大小和分级,但表现出“超突变”的分子特征和良好的预后。在此,为了强调在ECs中定义极点状态对患者的临床和治疗意义的重要性。
{"title":"POLE exonuclease domain mutations in endometrial carcinoma: a case report.","authors":"Maria Paola Pasciuto,&nbsp;Lara Felicioni,&nbsp;Claudia Zampacorta,&nbsp;Benedetta Ferro,&nbsp;Pietro Di Marino,&nbsp;Francesca Chiara Primavera,&nbsp;Alessandro Lucidi,&nbsp;Rebecca Rossetti,&nbsp;Mattia Barbareschi,&nbsp;Antonio Marchetti,&nbsp;Fiamma Buttitta,&nbsp;Emanuela D'Angelo","doi":"10.32074/1591-951X-872","DOIUrl":"https://doi.org/10.32074/1591-951X-872","url":null,"abstract":"<p><p>Endometrial carcinoma (EC) harboring POLE exonuclease domain mutations occurs in 5-15% of ECs and frequently affects young women with low body mass index (BMI). It presents at early stage as high grade endometrioid histotype with intense tumor infiltrating lymphocytes and has good clinical outcomes and favorable prognosis. In this article we report the case of a 32-year-old woman with endometriod EC (EEC) exhibiting a \"ultramutated\" molecular profile and an excellent prognosis despite tumor size and grading. Herein, to highlight the importance of defining POLE status in ECs for both clinical and therapeutic implications for patients.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"1 1","pages":"181-185"},"PeriodicalIF":3.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/cf/pathol-2023-03-181.PMC10462992.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10489926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
PATHOLOGICA
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1